Clinical trials: Relapsed
Multiple Myeloma
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT05007418
- Testing
- STI-1492
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sorrento Therapeutics, Inc.
Relapsing Remitting Multiple Sclerosis
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients before and after beginning Natalizumab.
- Trial name
- NCT01541618
- Testing
- MSDX Complex-1 Biomarker test
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MSDx, Inc.
Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
This study is an open-label, single-arm, prospective, multicenter, phase I/II clinical trial. It adopts the two-stage optimal design proposed by Bryant and Day to investigate the efficacy, safety, and in vivo pharmacokinetic…
- Trial name
- NCT07324889
- Testing
- CD19/BCMA CAR-T
- Volunteers
- 24 people
- Sponsor
- Yihao Wang
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic…
- Trial name
- IMPACT MS (NCT04466150)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Neoplasms, Breast
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
This study was designed to determine how effective and safe a new investigational drug, lapatinib, is in treating patients with treatment refractory or relapsed inflammatory breast cancer.
- Trial name
- NCT00105950
- Testing
- lapatinib
- Where
- 27 sites in United States, Belgium and 6 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
This study will find the highest acceptable treatment dose and timing of infusion of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with multiple myeloma.
- Trial name
- NCT02955550
- Testing
- rhIL-2, PNK-007
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celularity Incorporated
Anorexia Nervosa, Eating Disorders
Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa
This study will evaluate the effectiveness of fluoxetine versus placebo in reducing the rate of relapse of anorexia nervosa (AN) and enhancing the psychosocial and behavioral recovery of people who have been treated for AN.
- Trial name
- NCT00288574
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- New York State Psychiatric Institute
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
NK/T-Cell Lymphoma
A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.
- Trial name
- NCT04490590
- Testing
- Chidamide+ Etoposide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mingzhi Zhang
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in…
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NexCAR19 (NCT07502118)
- Testing
- Talikabtagene Autoleucel
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Health Institutes of Turkey
Non-Small Cell Lung Cancer NSCLC
Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-Trop2 U-CAR-NK Cells Therapy combined with Chemotherapy for Relapsed/Refractory Non-Small…
- Trial name
- NCT06454890
- Testing
- Anti-Trop2 CAR-NK cell
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Ewing's Sarcoma Family of Tumors
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors
- Trial name
- NCT00560235
- Testing
- CP-751,871
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 138 people
- Sponsor
- Pfizer
AML, t(8;21)
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
1. To evaluate the safety and tolerability of targeted AML1-ETO neoantigen cytotoxic T cells (CTL) in the treatment of relapsed or refractory acute myeloid leukemia . 2.
- Conditions
- AML, t(8;21), Neoantigen
- Trial name
- NCT06499025
- Testing
- targeted AML1-ETO neoantigen cytotoxic T cells (CTL), Cyclophosphamide injection, Decitabine Injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- BGI, China
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
This study will evaluate the safety and effectiveness of a combination of two antibodies, apolizumab and rituximab (Rituxan ), in treating B-cell lymphomas and chronic lymphocytic leukemia.
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT00022971
- Testing
- Apolizumab, Rituximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Dialysis Associated Peritonitis
Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis
Peritoneal dialysis (PD) is the first-line treatment of end stage renal disease (ESRD) in Hong Kong. Despite the advances in antibiotic therapy and connecting system, recurrent peritonitis remains the major cause of peritoneal…
- Trial name
- NCT01817309
- Testing
- endotoxin assay in peritoneal dialysis effluent
- Where
- Hong Kong
- Volunteers
- 325 people
- Sponsor
- Chinese University of Hong Kong
Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
- Trial name
- TRANSFORMS (NCT00340834)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,292 people
- Sponsor
- Novartis
Extensive-stage Small-cell Lung Cancer
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung…
- Trial name
- IDeate-Lung01 (NCT05280470)
- Testing
- Ifinatamab Deruxtecan (I-DXd)
- Where
- 58 sites in United States, China and 6 more
- Volunteers
- 187 people
- Sponsor
- Daiichi Sankyo
Iron Deficiency Anaemia
Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)
The objective is to monitor and quality assure the efficacy, including effects on quality of life, and safety of Monofer® in Chronic Kidney Disease and Inflammatory Bowel Disease patient populations when Monofer® is used…
- Trial name
- NCT02546154
- Testing
- 10% Iron Isomaltoside 1000
- Where
- United Kingdom
- Volunteers
- 359 people
- Sponsor
- Pharmacosmos UK Ltd
Head and Neck Squamous Cell Carcinoma
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.
- Trial name
- NCT04843098
- Testing
- TL117, Paclitaxel
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Suzhou Junde Biotechnology Co., Ltd
Hodgkin's Lymphoma
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma
This study is a multi-center, non-randomized, single-arm, open clinical trial.
- Trial name
- NCT04665063
- Testing
- Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.